In Cancer Biology,
Uncover immunotherapy biomarkers by visualizing the tumor microenvironment in context
Unmet Need in Cancer Immunotherapy
Despite the progress we’ve made in cancer immunotherapy, response rates continue to remain in the 20 to 30% range. There’s a need for biomarkers that can accurately predict response to treatment.
Understanding Cancer-Immune Biology
Immunotherapy treatments rely on the activation of the patient’s immune system to fight and kill tumor cells. The key to understanding more about tumor-immune biology lies in studying the complexity of the tumor microenvironment.
Transforming Your Approach to Cancer Biomarker Discovery
Multiplex immunofluorescence (mIF) enables the discovery of biomarker signatures from a single FFPE tissue section, while preserving the spatial context of the tumor microenvironment.
Spatial Phenotypic Signatures - Predicting
Of Tumor and Immune Cells
accurately measured with
Oncology Experts Discover Spatial Phenotypic
Signatures with mIF
Spatial Phenotypic Signatures, measured by mIF, outperform PD-L1 IHC and genomic biomarkers, in predicting immunotherapy response
In the translational research group, we are developing completely new types of tissue testing and imaging technology. These include the Phenoptics™ mIF workflow which we have implemented for our ImmunoProfile project at DFCI/BWH. This multi-omics approach captures far more immunological information within a tumor biopsy sample than has been accessible before.
Dr. Scott Rodig
Pathologist, Brigham & Women’s Hospital
Director, Center for Immuno-Oncology Tissue Biomarker Laboratory
Dana-Farber Cancer Institute
Professor Pathology, Harvard Medical School
The value of Spatial Phenotypic Signatures in translational and clinical research relies on a standardized and reproducible workflow.
MITRE: First Multi-Site mIF Standardization Study
6 leading institutions, across academia and pharma, established the inter- and intra-site reproducibility of the Phenoptics mIF workflow.
Validating mIF Panels for PD-L1 Testing
Studies by pathologists at Queen’s University show high concordance between DAB IHC and multiplex IF panels for profiling immunotherapy biomarkers.
Bringing mIF to the Clinic
Dr. Joe Yeong, Immunopathologist at the Singapore General Hospital predicts that multiplex immunofluorescence is poised to transform the cancer biomarker landscape.